Cure.
Overview
From RNA therapies to AI-enabled diagnostics, these companies are targeting one of medicine's biggest and most stubborn problems.
Cardiovascular disease kills more Americans than any other condition, affecting men and women across most racial and ethnic groups, according to the Centers for Disease Control and Prevention (CDC). The market that has grown around treating it reflects that scale: global revenues for cardiovascular therapeutics ran between $145 billion and $148 billion in 2024 to 2025 and are projected to reach roughly $180 billion by 2033.
Charles Dresser, Esq., a partner and patent attorney at Caldwell Law, calls cardiovascular diagnostics and therapeutics a "big, durable market," one with steady growth and current momentum driven by cardiometabolic drugs and AI-enabled diagnostics. Because the underlying disease burden is large, persistent, and not concentrated in any single region, he said the clinical and economic drivers are unlikely to shift. Companies best positioned to compete, according to Dresser, are those targeting large, well-defined patient populations with clear endpoints, and those that have mapped out regulatory approval and reimbursement alongside clinical evidence.
"In my experience advising AI-driven and software-enabled cardiovascular devices, the most scalable products are those which can be used in established clinical workflows and billing structures, especially those which can be used in place of more expensive interventions," he said.
Here are 10 companies that are building toward exactly that standard, across diagnostics, therapeutics, and the tools clinicians actually use.
Cardio Diagnostics
Blood-based epigenomic testing for coronary heart disease risk
HQ: Chicago, IL
Year Founded: 2017
Key Leaders: Meesha Dogan, PhD, Co-Founder and CEO; Rob Philibert, MD, Co-Founder and Chief Medical Officer; Tim Dogan, PhD, Chief Technology Officer
Number of Employees: ~17
Stage: Public
Financial Snapshot:The company’s market cap was about $5.84 million in April 2026.
Key Products: Epi+Gen CHD, a clinical blood test that assesses the three-year risk of a coronary heart disease event; PrecisionCHD, a clinical blood test that aids in the diagnosis of coronary heart disease; HeartRisk, a population cardiovascular risk intelligence platform that integrates HIPAA-compliant anonymized clinical, industry, claims, and geographic data to offer a comprehensive view of heart attack risk and coronary heart disease; CardioInnovate360 leverages AI and epigenetics to accelerate the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases
Recent Highlights: In January 2026, the company announced with Aimil Ltd., and Dr. Lal PathLabs, a strategic agreement to launch Cardio Diagnostics' PrecisionCHD test for the detection and management of coronary heart disease in India. The same month, the company announced a new partnership with the Southdale YMCA to bring expanded heart health education and advanced cardiovascular testing to their members and the broader Edina community.
HeartFlow
AI-powered coronary artery analysis from CT scans, no catheter required
HQ: San Francisco, CA
Year Founded: 2007
Origin Story: Charles Taylor and Christopher Zarins founded the company based on research that originated out of Stanford University.
Key Leaders: John Farquhar, President and CEO; Campbell Rogers, MD, EVP and Chief Medical Officer
Number of Employees: ~843
Stage: Public
Financial Snapshot: The company’s market cap was about $2.56 billion as of April 2026.
Key Products: HeartFlow One Platform, integrated, cloud-based platform that provides a suite of tools, including the FFRCT Analysis, RoadMap Analysis, and Plaque Analysis
Recent Highlights:In February 2026, the company announced that NBA legend Muggsy Bogues joined the effort to detect and manage coronary artery disease in retired players using AI-powered Heartflow Analysis. In March 2026, HeartFlow reported total revenue of $49.1 million, a 40% increase year-over-year
Tenaya Therapeutics
Gene therapies targeting the genetic causes of heart muscle disease
HQ: South San Francisco, CA
Year Founded: 2016
Origin Story: The company spun out of pioneering work in stem cell-derived heart tissue and regenerative medicine by cardiovascular scientists from the Gladstone Institutes and UT Southwestern.
Key Leaders: Faraz Ali, MBA, CEO; Whit Tingley, MD, PhD, CMO; Kee-Hong Kim, PhD, CTO
Number of Employees: ~70
Stage: Public
Financial Snapshot: The company’s market cap was about $162.75 million as of April 2026.
Key Products: TN-201, an AAV9-based gene therapy for treating genetic hypertrophic cardiomyopathy by delivering a functional MYBPC3 gene; TN-401, a gene therapy designed to treat arrhythmogenic right ventricular cardiomyopathy associated with PKP2 mutations; TN-301, a highly selective HDAC6 inhibitor developed for heart failure with preserved ejection fraction (HFpEF) and potential application in other muscular diseases.
Recent Highlights:In March 2026, the company announced that it presented preclinical data at MDA 2026 highlighting TN-301’s potential to correct skeletal and cardiac muscle decline in duchenne muscular dystrophy.
Cardurion Pharmaceuticals
Small-molecule drugs for heart failure and rare genetic arrhythmia
HQ: Burlington, MA
Year Founded: 2017
Key Leaders: Michael E. Mendelsohn, MD, Founder and Chief Strategy Officer; Peter S. Lawrence, JD, President and CEO; Howard K. Surks, MD, Chief Medical and Scientific Officer
Number of Employees: ~50
Stage: Series B
Financial Snapshot: The company has raised over $600 million over six rounds.
Notable Investors: Ascenta Capital; Blue Owl Capital; Delos Capital Partners; Digitalis Ventures; Farallon Capital Management; Bain Capital Life Sciences
Key Products: CRD-750 (PDE9 Inhibitor), a novel inhibitor currently in Phase 2 clinical trials (CYCLE trials) for heart failure with both reduced (HFrEF) and preserved (HFpEF) ejection fraction; CRD-4730 (CaMKII Inhibitor), a lead compound in Phase 2 clinical trials for catecholaminergic polymorphic ventricular tachycardia, a rare genetic arrhythmic disease; CRD-740 (PDE9 Inhibitor), an earlier PDE9 inhibitor evaluated in the Phase 2 CARDINAL-HF trial for heart failure
Recent Highlights: In September 2024, the company was named as one of the Endpoints 11 most promising private biotechnology companies of 2024. In August 2025, the company completed enrollment in Phase 2 CYCLE Trials Evaluating CRD‑750, a novel PDE9 inhibitor, in heart failure.
iRhythm Holdings
Long-term wearable ECG monitoring with AI-driven arrhythmia detection
HQ: San Francisco, CA
Year Founded: 2006
Origin Story: Founded by Uday Kumar, a 2005-06 Stanford Biodesign Innovation Fellow, to improve arrhythmia diagnosis.
Key Leaders: Quentin Blackford, President, CEO, and Director; Mintu Turakhia, MD, Chief Medical and Scientific Officer; Brian Lawrence, PhD, Chief Technology Officer
Number of Employees: ~2,400
Stage: Public
Financial Snapshot: The company’s market cap was about $3.96 billion as of April 2026.
Key Products: Zio Patch, a small, flexible, water-resistant, adhesive monitoring patch that records heart rhythms continuously for up to two weeks.
Recent highlights: In March 2026, the company announced results from three retrospective analyses that add to the growing body of clinical evidence supporting the benefits of its Zio ambulatory ECG monitoring service across patient populations.
AliveCor
Personal ECG devices with AI that detects atrial fibrillation and other rhythm abnormalities
HQ: Mountain View, CA
Year Founded: 2010
Key Leaders: Priya Abani, CEO; David E. Albert, MD, Founder and Chief Medical Officer; Siva Somayajula, Chief Technology Officer; Ben Green, MD, Chief Clinical Officer; Alfred Woo, Chief Product Officer
Number of Employees: ~200
Stage: Late-stage venture-backed company
Financial Snapshot: The company has raised roughly $318 million.
Notable Investors: Khosla Ventures, GE Healthcare Technologies, Pegasus Tech Ventures, Sweetwater Private Equity, Huami Corp, Mayo Clinic, Omron Healthcare
Key Products: KardiaMobile 6L device is a personal ECG solution that provides instant detection of Atrial Fibrillation, Bradycardia, Tachycardia, Sinus Rhythm with Supraventricular Ectopy, Sinus Rhythm with Premature Ventricular Contractions, Sinus Rhythm with Wide QRS, and Normal Sinus Rhythm in an ECG.
Recent Highlights: In April 2026, AliveCor partnered with WELL Health to bring rapid, cardiologist-reviewed ECG services to patients across Canada through the Kardia platform. In February 2026, the company partnered with Ametris to integrate AliveCor’s medical-grade cardiac monitoring solution, including the world’s first FDA-cleared 6-lead ECG device, into the Ametris Digital Health Technology (DHT) platform.
Cytokinetics
Drugs that directly target the cardiac muscle proteins driving heart failure and cardiomyopathy
HQ: South San Francisco, CA
Year Founded: 1998
Origin Story: Founded by four pioneers in the field of muscle biology: James Sabry, MD, PhD; James Spudich, PhD; Ronald Vale, PhD; and Lawrence S.B. Goldstein, PhD
Key Leaders: Robert I. Blum, President and CEO; Andrew Callos, EVP, Chief Commercial Officer
Number of Employees: ~673
Stage: Public
Financial Snapshot: The company’s market cap is about $8 billion as of April 2026.
Key Products: MYQORZO (aficamten), an oral small-molecule cardiac myosin inhibitor approved in the U.S., Europe, and China to treat adults with symptomatic obstructive HCM, approved by the FDA to reduce heart muscle hypercontractility; Omecamtiv Mecarbil, a cardiac myosin activator aimed at treating patients with heart failure with reduced ejection fraction.
Recent Highlights:In January 2026, the company Cytokinetics announced that it received approval in December 2025 from the FDA for MYQORZO for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms.
Cleerly
AI quantification of coronary artery plaque from CT imaging
HQ: Denver, CO
Year Founded: 2017
Key Leaders: James K. Min, MD, Founder and CEO; Jim Hartman, CCO; Udo Hoffmann, MD, CMO, CSO & Chief AI Officer
Number of Employees: ~290
Stage: Series C
Financial Snapshot: The company has raised $578 million across five funding rounds.
Notable Investors: Insight Partners; Battery Ventures; Fidelity Management; Novartis; Cigna Ventures; Double Point Ventures; Breyer Capital
Key Products: AI-driven, FDA-cleared digital platform that analyzes coronary computed tomography angiography
Recent Highlights: In March 2026, the company launched Cleerly PREVIEW, a new workflow-support enhancement designed to assist clinicians with case prioritization and streamline administrative processes, such as prior authorization, for coronary artery disease imaging. The same month, Cleerly presented findings from its multicenter INVICTUS registry at the recent European Congress of Radiology in Vienna, Austria. The findings aimed to evaluate the quantification and characterization of atherosclerosis by artificial intelligence-enabled quantitative computed tomography (AI-QCT) against “gold-standard” invasive imaging techniques such as intravascular ultrasound.
Eko Health
Digital stethoscopes with AI that flags structural heart conditions during routine exams
HQ: Emeryville, CA
Year Founded: 2013
Origin Story: While attending UC Berkeley to obtain a bioengineering degree, classmates Connor Landgraf, Jason Bellet, and Tyler Crouch decided to develop an improved stethoscope for their senior thesis.
Key Leaders: Connor Landgraf, Co-Founder and CEO; Jason Bellet, Co-Founder and Chief Business Officer; Steven Steinhubl, MD, Chief Medical Officer
Number of Employees: ~180
Stage: Late-stage venture capital
Financial Snapshot: In June 2024, raised $41 million in Series D funding and hasraised a total of about $195 million.
Notable Investors: Artis Ventures, EDBI, DigiTx Partners, Double Point Ventures, Highland Capital Partners, LG Technology Ventures, Mayo Clinic, Morningside Technology Ventures Limited, NTTVC, Questa Capital
Key Products: Eko CORE, a small attachment that turns an analog stethoscope into a digital one; 3M Littmann CORE Digital Stethoscope, which is a cardiology-grade stethoscope enhanced by Eko’s CORE digital technology; SENSORA platform supports clinicians by flagging structural murmurs and low ejection fraction during the physical exam
Recent Highlights: In July 2025, the American Medical Association issued a new Category III CPT code for Eko Health’s AI-enabled cardiac analysis platform, SENSORA.
HeartSciences
Wavelet-based ECG signal processing to detect cardiac dysfunction standard ECGs miss
HQ: Southlake, TX
Year Founded: 2008
Key Leaders: Andrew Simpson, CEO and Chairman; Mark Hilz, Chief Operating Officer; Danielle Watson, Chief Financial Officer
Number of Employees: ~16
Stage: Public
Financial Snapshot: The company has a market cap of about $6.53 million as of April 2026.
Key Products: MyoVista Wavelet ECG (wavECG), which uses AI and continuous wavelet transform (CWT) signal processing to detect cardiac dysfunction, specifically left ventricular diastolic dysfunction (LVDD); MyoVista Insights platform, a cloud-native, vendor-agnostic ECG management system that uses AI to improve cardiac diagnostic capabilities
Recent highlights: In February 2026, the company announced that the University of the West of England adopted its MyoVista Insights platform and MyoVista wavECG device as its exclusive ECG technologies to establish a Reference Center for ECG Education and Technology. In March 2026, the company announced that its MyoVista Insights platform has received Epic Toolbox designation for the ECG Management System category.
